Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed ...

Please provide your email address to receive an email when new articles are posted on . Patients with immune thrombocytopenia achieved durable platelet count expansion with rilzabrutinib.

Rilzabrutinib has been granted Fast Track designation for the treatment of immune thrombocytopenia. Rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has been granted Fast Track ...

Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or ...

Rilzabrutinib is an investigational, oral, reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...

Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...

Rilzabrutinib, a novel oral reversible Bruton's tyrosine kinase inhibitor, delivered rapid control of pemphigus disease activity accompanied by markedly reduced need for systemic corticosteroids in ...

Please provide your email address to receive an email when new articles are posted on . Rilzabrutinib demonstrated rapid, stable and durable platelet responses among patients with relapsed immune ...

Paris, December 7, 2024. Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, ...